JP2019535799A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535799A5 JP2019535799A5 JP2019528746A JP2019528746A JP2019535799A5 JP 2019535799 A5 JP2019535799 A5 JP 2019535799A5 JP 2019528746 A JP2019528746 A JP 2019528746A JP 2019528746 A JP2019528746 A JP 2019528746A JP 2019535799 A5 JP2019535799 A5 JP 2019535799A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment
- composition according
- disorders
- neurological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 108020001588 κ-opioid receptors Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426980P | 2016-11-28 | 2016-11-28 | |
| US62/426,980 | 2016-11-28 | ||
| US201762576435P | 2017-10-24 | 2017-10-24 | |
| US62/576,435 | 2017-10-24 | ||
| US201762585016P | 2017-11-13 | 2017-11-13 | |
| US62/585,016 | 2017-11-13 | ||
| PCT/IB2017/057418 WO2018096510A1 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535799A JP2019535799A (ja) | 2019-12-12 |
| JP2019535799A5 true JP2019535799A5 (https=) | 2021-01-14 |
| JP7051853B2 JP7051853B2 (ja) | 2022-04-11 |
Family
ID=60782279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528746A Active JP7051853B2 (ja) | 2016-11-28 | 2017-11-27 | ヘテロアリールフェノキシベンズアミドカッパオピオイドリガンド |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10316021B2 (https=) |
| EP (1) | EP3544972B8 (https=) |
| JP (1) | JP7051853B2 (https=) |
| CN (1) | CN110234638B (https=) |
| AU (1) | AU2017365123B2 (https=) |
| DK (1) | DK3544972T3 (https=) |
| ES (1) | ES2947293T3 (https=) |
| FI (1) | FI3544972T3 (https=) |
| HR (1) | HRP20230518T1 (https=) |
| HU (1) | HUE061945T2 (https=) |
| IL (1) | IL266962B (https=) |
| MX (1) | MX389806B (https=) |
| PH (1) | PH12019501172A1 (https=) |
| PL (1) | PL3544972T3 (https=) |
| PT (1) | PT3544972T (https=) |
| RS (1) | RS64258B1 (https=) |
| TW (1) | TWI720272B (https=) |
| WO (1) | WO2018096510A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585485A2 (en) | 2017-02-24 | 2020-01-01 | Xeniopro GmbH | Aromatic compounds which enhance notch signaling, for use in therapy |
| WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| PH12021552872A1 (en) * | 2020-04-05 | 2022-03-21 | Pfizer | Compounds and methods for the treatment of covid-19 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| WO2023170547A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| EP4489730B1 (en) | 2022-03-07 | 2026-01-21 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| PE20251585A1 (es) * | 2022-10-12 | 2025-06-16 | Adama Makhteshim Ltd | Proceso para la preparacion de derivados de aminopiridazina |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| JP2000159747A (ja) * | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| WO2000017162A1 (en) | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Novel thiol derivatives, process for producing the same and utilization thereof |
| IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
| KR101025633B1 (ko) | 2002-09-19 | 2011-03-30 | 일라이 릴리 앤드 캄파니 | 오피오이드 수용체 안타고니스트로서의 디아릴 에테르 |
| US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
| US7396943B2 (en) | 2003-03-07 | 2008-07-08 | Eli Lilly And Company | Opioid receptor antagonists |
| RU2366655C2 (ru) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
| ZA200700811B (en) | 2004-08-06 | 2008-10-29 | Otsuka Pharma Co Ltd | Aromatic compound |
| EP1849835B1 (en) | 2005-02-18 | 2017-08-30 | Nippon Soda Co., Ltd. | Organic-inorganic composite body |
| CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| DK2001456T3 (da) | 2006-04-04 | 2010-04-12 | Emodys Gmbh | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
| WO2009094260A1 (en) | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| CR11559A (es) | 2008-03-25 | 2010-10-20 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| JP2012512877A (ja) | 2008-12-18 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | セロトニン５−ｈｔ２ｂ受容体阻害剤 |
| HN2010001319A (es) | 2009-01-26 | 2013-01-15 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
| WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
| JP2015531382A (ja) | 2012-10-02 | 2015-11-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピロリジン |
| WO2015109080A1 (en) | 2014-01-15 | 2015-07-23 | Research Triangle Institute | Kappa-opioid receptor selective opioid receptor antagonists |
| US10118896B2 (en) | 2014-11-26 | 2018-11-06 | University Of Kansas | Antagonists of the kappa opioid receptor |
-
2017
- 2017-11-22 US US15/820,679 patent/US10316021B2/en active Active
- 2017-11-27 HR HRP20230518TT patent/HRP20230518T1/hr unknown
- 2017-11-27 RS RS20230453A patent/RS64258B1/sr unknown
- 2017-11-27 ES ES17818281T patent/ES2947293T3/es active Active
- 2017-11-27 DK DK17818281.2T patent/DK3544972T3/da active
- 2017-11-27 TW TW106141134A patent/TWI720272B/zh active
- 2017-11-27 PT PT178182812T patent/PT3544972T/pt unknown
- 2017-11-27 CN CN201780084763.0A patent/CN110234638B/zh active Active
- 2017-11-27 FI FIEP17818281.2T patent/FI3544972T3/fi active
- 2017-11-27 JP JP2019528746A patent/JP7051853B2/ja active Active
- 2017-11-27 PL PL17818281.2T patent/PL3544972T3/pl unknown
- 2017-11-27 HU HUE17818281A patent/HUE061945T2/hu unknown
- 2017-11-27 MX MX2019006220A patent/MX389806B/es unknown
- 2017-11-27 EP EP17818281.2A patent/EP3544972B8/en active Active
- 2017-11-27 AU AU2017365123A patent/AU2017365123B2/en active Active
- 2017-11-27 WO PCT/IB2017/057418 patent/WO2018096510A1/en not_active Ceased
-
2019
- 2019-05-28 IL IL266962A patent/IL266962B/en unknown
- 2019-05-28 PH PH12019501172A patent/PH12019501172A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535799A5 (https=) | ||
| IL269599B1 (en) | 11, 13- modified schistosoxins for pain treatment | |
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| JP2016515522A5 (https=) | ||
| HRP20210518T1 (hr) | Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava | |
| WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
| WO2016100157A3 (en) | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | |
| IL269310A (en) | Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| WO2017070689A3 (en) | Solabegron zwitterion and uses thereof | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| EP3589305C0 (en) | SPECIFIC INCREASE IN DOPAMINE SYNTHESIS BY TARGETING THE GUANYLATE CYCLASE 2C RECEPTOR IN THE TREATMENT OF PARKINSON'S DISEASE | |
| EA201791398A1 (ru) | Производные фумагиллола | |
| SG10201912846PA (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease | |
| MA40065A (fr) | N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| IT201700006355A1 (it) | Composizione per il trattamento dei disturbi gastrointestinali | |
| ZA201704287B (en) | 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of cns disorders | |
| HK1245077A1 (en) | Compositions and methods of treating a neurodegenerative disease | |
| ITUB20153076A1 (it) | Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento. |